Filter Your Results




Cognitive Effects of Amyotrophic Lateral Sclerosis Increase as Disease Progresses

Wednesday, September 12, 2018—Although it is often referred to as a neurologic disease that attacks the body and not the mind, cognitive effects in amyotrophic lateral sclerosis (ALS) exist and have been r…

FDA Approves of Oral Suspension of Riluzole for Patients With Amyotrophic Lateral Sclerosis

Monday, September 10, 2018—The Food and Drug Administration (FDA) has approved a new formulation of riluzole (Tiglutek; ITF Pharma, Berwyn, PA) for patients with amyotrophic lateral sclerosis (ALS). Thi…

Hereditary Neuropathy Foundation Hosting Patient-Focused Drug Development Meeting September 28th, 2018

Thursday, September 06, 2018—The Hereditary Neuropathy Foundation (HNF) is holding an externally-led, patient-focused drug development meeting for Charcot-Marie-Tooth disease (CMT) and inherited neuropath…

Lower Extremity Radicular Pain Relieved With Tetrahydrocannabinol

Wednesday, September 05, 2018—In a small (n = 17 men), double-blind, placebo-controlled study using a counterbalanced within-subjects design, treatment of patients with chronic neuropathic pain with d…

Nusinersen Effective Treatment for Type 1 Spinal Muscle Atrophy Even When Given at Age 7 Months and Up

Wednesday, August 29, 2018—Nusinersen (Spinraza; Biogen, Cambridge, MA), a novel therapy approved by the Food and Drug Administration (FDA) for treatment of patients with spinal muscle atrophy (SMA). Re…

First-in-Class RNAi Treatment for Hereditary Transthyretin-Mediated Amyloidosis

Wednesday, August 15, 2018—The US Food and Drug Administration (FDA) has approved patisiran (Onpattro; Alnylam Pharmaceuticals, Cambridge, MA) for treatment of polyneuropathy in adults with hereditary t…

Breaching the Blood-Brain Barrier: A Potential New Treatment Modality

Monday, July 30, 2018—In a small, yet groundbreaking, clinical trial, MR-guided focused ultrasound (MRgFUS) (ExablateNeuro; Insightec, Miami FL) was used to open the blood-brain barrier (BBB) safel…

Amyotrophic Lateral Sclerosis the Next Target for Antisense Oligonucleotide Therapy?

Thursday, July 26, 2018—Antisense oligonucleotide (ASO) therapy is a new class of treatment of people with illnesses caused by defects in a single gene. In this novel approach, instead of repairing o…


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.